Moxifloxacino Tevagen (Moxifloxacin)

Moxifloxacin blocks bacterial DNA gyrase and topoisomerase IV, enzymes required for DNA replication and transcription. By inhibiting these targets, it prevents bacterial cells from multiplying, leading to bacterial death and resolution of the infection.

The dosage of Moxifloxacino Tevagen is determined by the prescribing clinician based on the specific infection, patient age, weight, renal function, and other clinical factors. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Moxifloxacino Tevagen is classified as pregnancy category C, meaning it should be used only if the potential benefit justifies the potential risk to the fetus. It is excreted in breast milk, so breastfeeding mothers should discuss risks and alternatives with their healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Moxifloxacin offers a broader spectrum against Gram‑positive organisms and better activity in respiratory infections compared with older fluoroquinolones like ciprofloxacin. It also has a more favorable dosing schedule, often once daily, but shares class‑related safety considerations such as tendon risk and QT prolongation.

Moxifloxacino Tevagen should be stored at temperatures below 25 °C, in its original packaging, protected from moisture and direct sunlight. Keeping the product in a dry, cool environment helps maintain its stability and potency throughout its shelf life.

Moxifloxacino Tevagen is administered orally, typically as a tablet or oral suspension, depending on the marketed formulation. It should be taken with a full glass of water, and patients may be advised to avoid taking it with antacids that contain aluminum or magnesium.

Serious risks include tendon rupture, especially in the Achilles tendon, QT interval prolongation leading to cardiac arrhythmias, severe allergic reactions such as anaphylaxis, Clostridioides difficile‑associated diarrhea, and potential hepatic or neurological adverse events. Patients should seek immediate medical attention if they experience any of these symptoms.

Moxifloxacino Tevagen should be avoided in patients with a known hypersensitivity to moxifloxacin or other fluoroquinolones, those with a history of tendon disorders related to fluoroquinolone use, individuals taking other QT‑prolonging agents without monitoring, and patients with certain cardiac conditions where QT prolongation poses a high risk.